Search clinical trials for: Lopinavir/ritonavir (Kaletra)

Total 939 results

Abbott

Completed

Drug Use Investigation of Kaletra

Human Immunodeficiency Virus

Japan
Abbott

Completed

Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China

HIV-1 Infections

China
Abbott

Completed

Special Investigation of Kaletra in Pregnant Women

Human Immunodeficiency Virus

Japan
Abbott

Completed

Evaluation of Kaletra Therapy Over the Long-term

Human Immunodeficiency Virus

Germany
Oswaldo Cruz Foundation
Ministry of Health, Brazil

Completed

Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy

HIV Infections | Pregnancy

Brazil
AbbVie (prior sponsor, Abbott)

Completed

Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score

HIV Infection

Puerto Rico
University College, London
LifeArc

Completed

FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals (FLARE)

COVID-19

United Kingdom
Fundacion SEIMC-GESIDA
Abbott

Completed

Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r (PEKARI)

HIV Infections | HIV/HCV Co-infection

Spain
Eunice Kennedy Shriver National Institute of Child...
American Association of Colleges of Pharmacy

Completed

Lopinavir/Ritonavir (Kaletra) PK in Children

HIV Infections | HIV/AIDS Treatment

United States
AbbVie (prior sponsor, Abbott)

Completed

Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program

Human Immunodeficiency Virus Infection
Royal Free Hampstead NHS Trust
Roche Pharma AG

Completed

Lopinavir Capsules to Kaletra or Invirase Tablets (LoCKIT)

HIV Infections

United Kingdom
ANRS, Emerging Infectious Diseases
Abbott

Completed

Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva

HIV Infections

France
Abbott

Completed

Long-term Effectiveness and Safety in Hepatitis-co-infected Patients

Human Immunodeficiency Virus-Infection

Germany
University of Miami
Oswaldo Cruz Foundation

Terminated

Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin

Tuberculosis | AIDS

Brazil
National Institute of Allergy and Infectious Diseases...

Completed

A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines

HIV

United States, South Africa, Thailand, Brazil
Bamrasnaradura Infectious Diseases Institute

Completed

Ritonavir-boosted Lopinavir Monotherapy

HIV

Thailand
ViiV Healthcare
Pfizer

Completed

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Human Immunodeficiency Virus-1

United States, Spain, Germany
National Institutes of Health Clinical Center (CC)

Completed

Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil (GEM-PK)

Healthy Volunteers

United States
Unity Health Toronto

Active, not recruiting

COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir (CORIPREV-LR)

Coronavirus Infections | Post-exposure Prophylaxis

Canada
Phoenix Children's Hospital
Abbott

Completed

Comparison of Liquid Kaletra and Low Dose Kaletra Tablets

HIV Infections

United States
Merck Sharp & Dohme LLC

Terminated

MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)

HIV Infection
University of Maryland, Baltimore

Terminated

Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study

HIV

United States
Massachusetts General Hospital
Bristol-Myers Squibb

Completed

Metabolic Effects of Switching Kaletra to Boosted Reyataz

HIV Infections

United States
Abbott

Completed

Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects

Human Immunodeficiency Virus Infections

United States
Abbott

Completed

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients (KALEAD)

HIV Infection

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Withdrawn

Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-Confirmed
University of California, San Francisco

Completed

Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir) (AP6142)

Human Immunodeficiency Virus | Drug Interactions

United States
AbbVie (prior sponsor, Abbott)

Completed

Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients

Human Immunodeficiency Virus

Mexico
Drugs for Neglected Diseases
University of Cape Town; Medecins Sans Frontieres, Netherlands; UBS Optimus Foundation and other collaborators

Completed

Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB

Acquired Immunodeficiency Syndrome | Tuberculosis

South Africa
Temple University
Pfizer; Abbott

Terminated

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) (KALMAR)

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.

Infection, Human Immunodeficiency Virus

Argentina
St Stephens Aids Trust
University of Liverpool

Suspended

PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers

HIV

United Kingdom
Radboud University Medical Center

Completed

Pharmacokinetic Study of Two Generic Co-formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF) (SURF)

HIV Infections

Netherlands
University of Alberta
Canadian Institutes of Health Research (CIHR); Gilead Sciences; Abbott

Completed

Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis (HAART)

Primary Biliary Cirrhosis

Canada
Fundación Huésped
Abbott

Completed

Induction-maintenance of Lopinavir/r in HIV-infected Subjects

HIV Infections

Canada, Argentina, Mexico
Abbott

Completed

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

Human Immunodeficiency Virus Infections

United States, Australia, Belgium, Canada, Czech Republic, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Puerto Rico, Russian Federation, Singapore, Spain, Switzerland, Taiwan, United Kingdom
University of North Carolina, Chapel Hill

Completed

The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet

Pregnancy | HIV

United States
Vanderbilt University Medical Center
AbbVie

Completed

Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 (TREATNOW)

COVID-19

United States
Rodwick, Barry M., M.D.
Abbott

Terminated

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc (PALM)

HIV Infections | Acquired Immunodeficiency Syndrome

United States
University of Cincinnati
Gilead Sciences; Abbott

Completed

Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection

HIV Infections

United States
Guangzhou 8th People's Hospital

Completed

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection (ELACOI)

Coronavirus Infections

China
Asan Medical Center

Terminated

Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)

COVID-19

Korea, Republic of
World Medicine ILAC SAN. ve TIC. A.S.
Novagenix Bioanalytical Drug R&D Center; Farmagen Ar-Ge Biyot. Ltd. Sti

Completed

Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions (Orvical)

Bioequivalence

Turkey
ViiV Healthcare

Terminated

GW873140 In Combination With Kaletra In HIV Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Germany, France, Canada, Spain, Italy, Portugal, United Kingdom, Denmark, Netherlands
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole

Healthy Volunteers | Pharmacokinetics of Isavuconazole | Pharmacokinetics of Lopinavir/Ritonavir

United States
Saint Michael's Medical Center
Abbott

Completed

Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients

HIV Infections

United States
Baqiyatallah Medical Sciences University

Completed

Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19

COVID-19 | Hydroxychloroquine | Favipiravir | Kaletra | Lopinavir/Ritonavir

Iran, Islamic Republic of
Allina Health System

Completed

Raltegravir Kaletra Pharmacokinetics (RAL-KAL)

Healthy

United States
Daniel Podzamczer

Completed

Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily

HIV

Spain
University of Roma La Sapienza
Istituto Superiore di Sanità

Unknown

Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy

HIV Infection

Italy

Search clinical trials for: Lopinavir/ritonavir (Kaletra)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations